Research Report


研究部 (Research Team)

Phone: +86 21 51699400-105  
Email Enquiry For Research Report and Business enquiry

Report Review of Dec 2017

Wednesday, January 03, 2018 Views1455
Report Review of Dec 2017


Air & Automobiles (ZhangJing)

Environmental protection & New energy(Wangyannan)

Healthcare & Consumer (Eurus Zhou)

Automobile & Air (ZhangJing)

This month I released 1 macro strategy report and 2 equity reports including China Southern Airline CSA (1055 HK) and Air China AC(753 HK), which got success by their unique Competitive edge.

In 2017, the world economy showed a steady recovery. We expect the U.S. economy to continue recovering steadily in 2018 and normalize its monetary policy. After the better-than-expected 2017, the European economy will continue its steady recovery and gradually withdraw from its QE. Japan will still maintain a loose monetary tone. In emerging markets, there will be differentiation and China's economy will continue to progress steadily.

On the premise of the improvement of the supply and demand pattern, we expressed cautious optimism for the promotion of the industry next year. In August, CSA raised H-shares and introduced U.S. airline strategy investors, which was expected to help to develop the company's Euro-American flight. At the same time, the company’s project of raising RMB13.3 billion is moving forward, which will further increase assets when finished. The "accumulate" rating is given.

Environmental protection (Wang Yannan)

This month , I have issued 4 research reports, namely LK(600388.SH), BGE(603588.SH),WEIMING(603568.SH),CEB(1257.HK). We tend to highly recommend BGE(603588.SH). Beijing GeoEnviron Engineering & Technology has strong overall strength in the soil remediation field, and at the same time, has accelerated its layouts in the dangerous wastes disposal and garbage burning fields, bringing sufficient momentum for continuous result growth. A few days ago, after the Company resumed trading by terminating its purchasing Shenzhen Shentou Environmental Technology Co, Ltd., the risk of falling short of expectations has been released to a large extent, and the controlling shareholders, supervisors and senior executives successively held more shares to show to the market their confidence in the long-term development of the company.

Healthcare & Consumer (Eurus Zhou)

This month I released 3 equity reports, including Shanghai Pharma (2607.HK), Yunnan Baiyao (000538.CH) and Anta Sports (2020.HK). We tend to highly recommend Shanghai Pharma (2607.HK) and Yunnan Baiyao (000538.CH). As up to end of Sep, Shanghai Pharma reported revenue/net profit YoY growth of 9.41/9.42%, and we see improving operation with rising net operating cash inflow of RMB1.85bn (+0.54bn YoY). In Nov 2017, the company announced that its subsidiary would acquire 100% of Cardinal China (a foreign-capital pharmaceutical distributor in China). We estimate that inclusion of Cardinal business will enlarge the distribution revenue by c.15% in 18E. We see that distribution business turnover grew at 8.33% YoY in 9M17 and the company continues to expand the hospital supply chain innovation services. Manufacturing business grew at 18.7% YoY as up to end of Sep. We expect the manufacturing business to maintain quick growth as the company adheres to focus on key products and to strengthen the academic marketing-oriented strategy. 26 key products are expected to achieve more than 100mn sales in 17E. After the composite ownership reform, Yunnan Baiyao introduces more market-oriented decision making system and raises compensation to management. Manufacturing business reported FY11-16 CAGR 15.68% with average GPM 61.8%, while distribution segment recorded FY11-16 CAGR 14.8% with average GPM 6.81%. During the first half, manufacturing business grew at 9.5% YoY with GPM 66% (+4.79ppts) and distribution business achieved 17.5% YoY growth with increasing GPM 7.07% (+1.07ppts). We expect the topline to grow at 15.5%/13.4% in 17E/18E.

Click Here for PDF format...

Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources believed to be reliable. However, we do not verify such information. We do not guarantee its accuracy or completeness, nor do we take responsibility for any loss occasioned by reliance placed upon the contents hereof. Any statements nonfactual in nature constitute only current opinions, which are subject to change. Phillip Securities (HK) Ltd (or one of its affiliates) or their officers, directors, analysts, or employees may have positions in securities or commodities referred to herein, and may, as principal or agent, buy and sell such securities or commodities. An employee, analyst, officer, or a director of Phillip Securities (HK) Ltd, or its affiliates, may serve as a director for companies mentioned in this report. Neither the information nor opinion expressed in this report shall constitute a solicitation to buy or sell any securities. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. This firm (or one of its affiliates) may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report.
There are risks inherent in international investments, which may make such investments unsuitable for certain clients. These include, for example, economic, political, currency exchange rate fluctuations, and limited availability of information on international securities. We recommend that you obtain the advice of your Financial Advisor regarding this or other investment in order to conform to your financial resources and risk preference
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email :

Enquiry & Support
Louis Talk
Investor Notes
Free Subscribe
Contact Us